Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)
| Autor: | L. M. Blank, Alexander Lila, T. V. Beketova |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
lcsh:Diseases of the musculoskeletal system Immunology Diseases of the musculoskeletal system vasculitis Cell therapy 03 medical and health sciences rituximab 0302 clinical medicine Rheumatology Internal medicine b cells Immunology and Allergy Medicine Stage (cooking) B cell 030203 arthritis & rheumatology granulomatosis with polyangiitis business.industry anca medicine.disease medicine.anatomical_structure RC925-935 covid-19 Respiratory failure Rituximab lcsh:RC925-935 business Vasculitis Granulomatosis with polyangiitis 030217 neurology & neurosurgery medicine.drug Systemic vasculitis |
| Zdroj: | Научно-практическая ревматология, Vol 0, Iss 0 (2018) Научно-практическая ревматология, Vol 58, Iss 4, Pp 456-462 (2020) |
| ISSN: | 1995-4492 1995-4484 |
| DOI: | 10.47360/1995-4484-2020-456-462 |
| Popis: | Despite numerous publications on COVID-19, at present, conceptual thinking of the problem is only at a nascence stage. Treatment of patients with ANCA-associated systemic vasculitis (AAV) during the COVID-19 pandemic is one of the relevant issues. Management of COVID-19 in AAV patients undergoing anti-B cell therapy with rituximab (RTM) requires comprehensive reasoning. This paper presents a case report about COVID-19 in a 59-year-old female with AAV in remission, who was previously treated with RTM. COVID-19 was diagnosed one month after the last RTM administration; there were moderate bilateral pneumonia, fever, and extrapulmonary manifestations, including lesions of the gastrointestinal tract and central nervous system. Clinical outcome of COVID-19 was favorable, with no signs of respiratory failure, and CRP values did not exceed 29 mg/l. We discuss published data on RTM use during COVID-19 pandemic and the effects of B cells and their depletion on the course and outcomes of COVID-19. Our case report and available published data do not allow to consider RTM therapy as a factor associated with severe course of COVID-19 and adverse outcome. Further analysis of COVID-19 in patients with AAV and other rheumatic diseases is important. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|